• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Alcon licenses anti-infective compound

Article

Fort Worth, TX-Alcon Laboratories' affiliate Alcon Manufacturing Ltd. has signed a collaboration and licensing agreement with NovaCal Pharmaceuticals to research, develop, and commercialize NovaCal's novel Aganocide topical compounds to treat bacterial, viral, and fungal infections in the eye, ear, and sinus.

Fort Worth, TX-Alcon Laboratories' affiliate Alcon Manufacturing Ltd. has signed a collaboration and licensing agreement with NovaCal Pharmaceuticals to research, develop, and commercialize NovaCal's novel Aganocide topical compounds to treat bacterial, viral, and fungal infections in the eye, ear, and sinus.

Related Videos
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.